Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or
patients with burning mouth syndrome participate in this study. The aim of the study is to
compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered
with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to
determine if there are sex differences in these two drug regimens. Drugs will be administered
with single-use intranasal spray devices. All participants will receive two sprays (one spray
per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be
naloxone in half the participants and placebo in the other half.